A Study to Learn More About How Well the Study Treatment Finerenone Works
Phase 3
219
about 5.4 years
0.5–17
19 sites in AZ, CA, DC +12
About this study
This trial is testing whether finerenone, taken with an ACE inhibitor or angiotensin receptor blocker, helps reduce protein in urine for children with chronic kidney disease. Researchers will also examine how well finerenone works and its safety profile.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Finerenone (Kerendia, BAY94-8862)
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
finerenone
oral (Oral Tablet)
Primary: Percent change in Urinary protein-to-creatinine ratio (UPCR) reduction from baseline to day 180+/-7
Secondary: Change in eGFR from baseline to day 180±7, Change in serum creatinine from baseline to day 180±7, Change in systolic blood pressure from baseline to day 180±7, Number participants with treatment emergent adverse events (TEAEs）, Pharmacokinetics (PK) finerenone AUCτ,md, Pharmacokinetics (PK) finerenone Cmax, md
Renal